Announcements Trials
Browse Landscape

Status

Completed 231Recruiting 131Unknown 85Active not recruiting 60Terminated 53Withdrawn 20Not yet recruiting 19Enrolling by invitation 6No longer available 4Approved for marketing 2Suspended 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 17Gastrointestinal 13Other hematologic neoplasm 12Genitourinary 12Lymphoid 10Breast 10CNS 7Plasma cell 6Head & Neck 5Endocrine 5Sarcoma 4Tumor-Agnostic 3Dermatologic 3NET 2Myeloid 2Gynecologic 2Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × NET × Clear all
NCT04334837 2020-10-09

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Curium US LLC

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡